Individualized tumor response testing for prediction of response to paclitaxel and cisplatin chemotherapy in patients with advanced gastric cancer

Jee Hyun Kim, Keun Wook Lee, Yeul Hong Kim, Kyung Hee Lee, Do Youn Oh, Joonhee Kim, Sung Hyun Yang, Seock Ah Im, Sung Ho Choi, Yung Jue Bang

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The purpose of our study was to determine the most accurate analytic method to define in vitro chemosensitivity, using clinical response as reference standard in prospective clinical trial, and to assess accuracy of adenosine triphosphate-based chemotherapy response assay (ATP-CRA). Forty-eight patients with chemo-naïve, histologically confirmed, locally advanced or metastatic gastric cancer were enrolled for the study and were treated with combination chemotherapy of paclitaxel 175 mg/m2 and cisplatin 75 mg/m2 for maximum of six cycles after obtaining specimen for ATP-CRA. We performed the receiver operator characteristic curve analysis using patient responses by WHO criteria and ATP-CRA results to define the method with the highest accuracy. Median progression free survival was 4.2 months (95% confidence interval [CI]: 3.4-5.0) and median overall survival was 11.8 months (95% CI: 9.7-13.8) for all enrolled patients. Chemosensitivity index method yielded highest accuracy of 77.8% by ROC curve analysis, and the specificity, sensitivity, positive and negative predictive values were 95.7%, 46.2%, 85.7%, and 75.9%. In vitro chemosensitive group showed higher response rate (85.7% vs. 24.1%) (P=0.005) compared to chemoresistant group. ATP-CRA could predict clinical response to paclitaxel and cisplatin chemotherapy with high accuracy in advanced gastric cancer patients. Our study supports the use of ATP-CRA in further validation studies.

Original languageEnglish
Pages (from-to)684-690
Number of pages7
JournalJournal of Korean Medical Science
Volume25
Issue number5
DOIs
Publication statusPublished - 2010 May 1

Fingerprint

Stomach Neoplasms
Drug Therapy
Adenosine Triphosphate
Neoplasms
ROC Curve
Confidence Intervals
Validation Studies
Paclitaxel
Combination Drug Therapy
Cisplatin
Disease-Free Survival
TP protocol
Clinical Trials
Sensitivity and Specificity
Survival
In Vitro Techniques

Keywords

  • Antineoplastic agents
  • Antitumor
  • Cisplatin
  • Drug screening assays
  • Paclitaxel
  • Sensitivity and specificity
  • Stomach neoplasms
  • Therapeutic use

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Individualized tumor response testing for prediction of response to paclitaxel and cisplatin chemotherapy in patients with advanced gastric cancer. / Kim, Jee Hyun; Lee, Keun Wook; Kim, Yeul Hong; Lee, Kyung Hee; Oh, Do Youn; Kim, Joonhee; Yang, Sung Hyun; Im, Seock Ah; Choi, Sung Ho; Bang, Yung Jue.

In: Journal of Korean Medical Science, Vol. 25, No. 5, 01.05.2010, p. 684-690.

Research output: Contribution to journalArticle

Kim, Jee Hyun ; Lee, Keun Wook ; Kim, Yeul Hong ; Lee, Kyung Hee ; Oh, Do Youn ; Kim, Joonhee ; Yang, Sung Hyun ; Im, Seock Ah ; Choi, Sung Ho ; Bang, Yung Jue. / Individualized tumor response testing for prediction of response to paclitaxel and cisplatin chemotherapy in patients with advanced gastric cancer. In: Journal of Korean Medical Science. 2010 ; Vol. 25, No. 5. pp. 684-690.
@article{85583f55707d44e7b888d469f9136690,
title = "Individualized tumor response testing for prediction of response to paclitaxel and cisplatin chemotherapy in patients with advanced gastric cancer",
abstract = "The purpose of our study was to determine the most accurate analytic method to define in vitro chemosensitivity, using clinical response as reference standard in prospective clinical trial, and to assess accuracy of adenosine triphosphate-based chemotherapy response assay (ATP-CRA). Forty-eight patients with chemo-na{\"i}ve, histologically confirmed, locally advanced or metastatic gastric cancer were enrolled for the study and were treated with combination chemotherapy of paclitaxel 175 mg/m2 and cisplatin 75 mg/m2 for maximum of six cycles after obtaining specimen for ATP-CRA. We performed the receiver operator characteristic curve analysis using patient responses by WHO criteria and ATP-CRA results to define the method with the highest accuracy. Median progression free survival was 4.2 months (95{\%} confidence interval [CI]: 3.4-5.0) and median overall survival was 11.8 months (95{\%} CI: 9.7-13.8) for all enrolled patients. Chemosensitivity index method yielded highest accuracy of 77.8{\%} by ROC curve analysis, and the specificity, sensitivity, positive and negative predictive values were 95.7{\%}, 46.2{\%}, 85.7{\%}, and 75.9{\%}. In vitro chemosensitive group showed higher response rate (85.7{\%} vs. 24.1{\%}) (P=0.005) compared to chemoresistant group. ATP-CRA could predict clinical response to paclitaxel and cisplatin chemotherapy with high accuracy in advanced gastric cancer patients. Our study supports the use of ATP-CRA in further validation studies.",
keywords = "Antineoplastic agents, Antitumor, Cisplatin, Drug screening assays, Paclitaxel, Sensitivity and specificity, Stomach neoplasms, Therapeutic use",
author = "Kim, {Jee Hyun} and Lee, {Keun Wook} and Kim, {Yeul Hong} and Lee, {Kyung Hee} and Oh, {Do Youn} and Joonhee Kim and Yang, {Sung Hyun} and Im, {Seock Ah} and Choi, {Sung Ho} and Bang, {Yung Jue}",
year = "2010",
month = "5",
day = "1",
doi = "10.3346/jkms.2010.25.5.684",
language = "English",
volume = "25",
pages = "684--690",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "5",

}

TY - JOUR

T1 - Individualized tumor response testing for prediction of response to paclitaxel and cisplatin chemotherapy in patients with advanced gastric cancer

AU - Kim, Jee Hyun

AU - Lee, Keun Wook

AU - Kim, Yeul Hong

AU - Lee, Kyung Hee

AU - Oh, Do Youn

AU - Kim, Joonhee

AU - Yang, Sung Hyun

AU - Im, Seock Ah

AU - Choi, Sung Ho

AU - Bang, Yung Jue

PY - 2010/5/1

Y1 - 2010/5/1

N2 - The purpose of our study was to determine the most accurate analytic method to define in vitro chemosensitivity, using clinical response as reference standard in prospective clinical trial, and to assess accuracy of adenosine triphosphate-based chemotherapy response assay (ATP-CRA). Forty-eight patients with chemo-naïve, histologically confirmed, locally advanced or metastatic gastric cancer were enrolled for the study and were treated with combination chemotherapy of paclitaxel 175 mg/m2 and cisplatin 75 mg/m2 for maximum of six cycles after obtaining specimen for ATP-CRA. We performed the receiver operator characteristic curve analysis using patient responses by WHO criteria and ATP-CRA results to define the method with the highest accuracy. Median progression free survival was 4.2 months (95% confidence interval [CI]: 3.4-5.0) and median overall survival was 11.8 months (95% CI: 9.7-13.8) for all enrolled patients. Chemosensitivity index method yielded highest accuracy of 77.8% by ROC curve analysis, and the specificity, sensitivity, positive and negative predictive values were 95.7%, 46.2%, 85.7%, and 75.9%. In vitro chemosensitive group showed higher response rate (85.7% vs. 24.1%) (P=0.005) compared to chemoresistant group. ATP-CRA could predict clinical response to paclitaxel and cisplatin chemotherapy with high accuracy in advanced gastric cancer patients. Our study supports the use of ATP-CRA in further validation studies.

AB - The purpose of our study was to determine the most accurate analytic method to define in vitro chemosensitivity, using clinical response as reference standard in prospective clinical trial, and to assess accuracy of adenosine triphosphate-based chemotherapy response assay (ATP-CRA). Forty-eight patients with chemo-naïve, histologically confirmed, locally advanced or metastatic gastric cancer were enrolled for the study and were treated with combination chemotherapy of paclitaxel 175 mg/m2 and cisplatin 75 mg/m2 for maximum of six cycles after obtaining specimen for ATP-CRA. We performed the receiver operator characteristic curve analysis using patient responses by WHO criteria and ATP-CRA results to define the method with the highest accuracy. Median progression free survival was 4.2 months (95% confidence interval [CI]: 3.4-5.0) and median overall survival was 11.8 months (95% CI: 9.7-13.8) for all enrolled patients. Chemosensitivity index method yielded highest accuracy of 77.8% by ROC curve analysis, and the specificity, sensitivity, positive and negative predictive values were 95.7%, 46.2%, 85.7%, and 75.9%. In vitro chemosensitive group showed higher response rate (85.7% vs. 24.1%) (P=0.005) compared to chemoresistant group. ATP-CRA could predict clinical response to paclitaxel and cisplatin chemotherapy with high accuracy in advanced gastric cancer patients. Our study supports the use of ATP-CRA in further validation studies.

KW - Antineoplastic agents

KW - Antitumor

KW - Cisplatin

KW - Drug screening assays

KW - Paclitaxel

KW - Sensitivity and specificity

KW - Stomach neoplasms

KW - Therapeutic use

UR - http://www.scopus.com/inward/record.url?scp=77955291241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955291241&partnerID=8YFLogxK

U2 - 10.3346/jkms.2010.25.5.684

DO - 10.3346/jkms.2010.25.5.684

M3 - Article

VL - 25

SP - 684

EP - 690

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 5

ER -